Cytek Biosciences (CTKB) EBIAT (2020 - 2025)
Cytek Biosciences (CTKB) has disclosed EBIAT for 6 consecutive years, with -$44.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 557.08% year-over-year to -$44.1 million, compared with a TTM value of -$66.5 million through Dec 2025, down 1005.3%, and an annual FY2025 reading of -$66.5 million, down 1005.3% over the prior year.
- EBIAT was -$44.1 million for Q4 2025 at Cytek Biosciences, down from -$5.5 million in the prior quarter.
- Across five years, EBIAT topped out at $9.6 million in Q4 2024 and bottomed at -$44.1 million in Q4 2025.
- Average EBIAT over 5 years is -$4.0 million, with a median of -$1.7 million recorded in 2021.
- Peak annual rise in EBIAT hit 419.14% in 2022, while the deepest fall reached 2215.69% in 2022.
- Year by year, EBIAT stood at -$1.2 million in 2021, then soared by 419.14% to $3.7 million in 2022, then skyrocketed by 48.01% to $5.5 million in 2023, then soared by 75.23% to $9.6 million in 2024, then plummeted by 557.08% to -$44.1 million in 2025.
- Business Quant data shows EBIAT for CTKB at -$44.1 million in Q4 2025, -$5.5 million in Q3 2025, and -$5.6 million in Q2 2025.